No Data
No Data
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 29% But Its Business Still Trails The Industry
Express News | Checkpoint Therapeutics Announces FDA Approval of Unloxcyt™ (Cosibelimab-Ipdl)
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (Cosibelimab-ipdl)
Fortress Solutions Names Dan Lakey as Chief Revenue Officer to Drive Strategic Growth and Strengthen FortressONE Platform
Press Release: Fortress Acquires Infra Pipe Solutions, Leading Manufacturer of HDPE Pipes and Structures
A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Cuts Target Price to $4
No Data
HannChau : any thought on BCTX?
Jaguar8 OP HannChau : I’m hoping it will recover too since it closed its offering today
HannChau Jaguar8 OP : haha, i went in again. I think it will go back to 1 soon
S2ET0 HannChau : 我還在1.04
Jaguar8 OP HannChau : I’ll just re-enter PM hoping no offering is announce over the weekend
View more comments...